Spots Global Cancer Trial Database for node negative
Every month we try and update this database with for node negative cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | NCT00887536 | Breast Cancer | bevacizumab docetaxel doxorubicin cyclophosphamid... pegfilgrastim | 18 Years - 70 Years | NSABP Foundation Inc | |
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay | NCT01899079 | Breast Cancer | - | NanoString Technologies, Inc. | ||
Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience | NCT05950737 | Oral Cavity Squ... | Sentinel node b... | 18 Years - 75 Years | Tata Memorial Hospital | |
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | NCT00887536 | Breast Cancer | bevacizumab docetaxel doxorubicin cyclophosphamid... pegfilgrastim | 18 Years - 70 Years | NSABP Foundation Inc | |
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | NCT02625935 | Breast Cancer | - | NanoString Technologies, Inc. | ||
Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer | NCT02992574 | Breastcancer | Post Mastectomy... | 18 Years - 80 Years | Tata Memorial Centre | |
A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay | NCT01899079 | Breast Cancer | - | NanoString Technologies, Inc. | ||
Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer | NCT02992574 | Breastcancer | Post Mastectomy... | 18 Years - 80 Years | Tata Memorial Centre |